Jensen H V, Holm J, Davidsen K, Toftegaard L, Aggernaes H, Bjørum N
Psychiatry Department, Righospitalet, Copenhagen, Denmark.
Psychopharmacology (Berl). 1995 Dec;122(3):317-20. doi: 10.1007/BF02246555.
Urinary excretion of albumin and transferrin was determined by means of sensitive immunochemical methods in 40 manic-depressive patients prior to and following 6 months of daily or alternate-day lithium carbonate treatment. The median dose of lithium carbonate was 700 mg in the daily treatment group and 1200 mg in the alternate-day group, the corresponding median 12-h serum lithium concentration being 0.6 mmol l-1 and 0.7 mmol l-1, respectively. Urinary excretion of albumin and transferrin was significantly elevated in the lithium-treated patients as compared to a control group (Mann-Whitney). The change in urinary albumin:creatinine and transferrin:creatinine ratios between allocation and 6 months of treatment did not correlate significantly with the lithium dosing schedule (multiple linear regression), but did correlate with total lithium carbonate dose. In conclusion, the study provides no evidence of any difference in glomerular function (permeability) in the daily and alternate-day lithium dosing schedules, and lends no support to the hypothesis that alternate-day treatment diminishes the effect of lithium on renal function.
采用灵敏的免疫化学方法，对40例躁郁症患者在每日或隔日服用碳酸锂治疗6个月之前和之后的尿白蛋白和转铁蛋白排泄情况进行了测定。每日治疗组碳酸锂的中位剂量为700毫克，隔日治疗组为1200毫克，相应的12小时血清锂中位浓度分别为0.6毫摩尔/升和0.7毫摩尔/升。与对照组相比（曼-惠特尼检验），接受锂治疗的患者尿白蛋白和转铁蛋白排泄显著升高。从分配治疗到治疗6个月期间，尿白蛋白:肌酐和转铁蛋白:肌酐比值的变化与锂给药方案（多元线性回归）无显著相关性，但与碳酸锂总剂量相关。总之，该研究没有提供证据表明每日和隔日锂给药方案在肾小球功能（通透性）方面存在任何差异，也不支持隔日治疗会减弱锂对肾功能影响这一假设。
